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EXPERIMENTAL THERAPY OF CHRONIC PORPHYRIA
WITH VITAMIN B12*
CALVIN J. DILLAHA, M.D. AND WILLIAM HICKLIN, B.S., M.A.
Porphyria, although a relatively rare disease, has since the description of the
original case by Fischer and co-workers (1) continued to attract interest. This is
due undoubtedly to the very nature of the disease with its bizarre biochemical
changes and varied clinical pictures. Porphyria is characterized clinically by the
excretion of uroporphyrin in large amounts in the urine and feces along with in-
creased amounts of coproporphyrin. The uroporphyrin may vary in its chemical
form but its presence is essential for a diagnosis of porphyria.
On the basis of biochemical and clinical features, porphyria may be divided
into three types:
1. Congenital: Excretion of large amounts of free uroporphyrin and copro-
porphyrin. Photosensitivity is present early in life, and is usually quite marked
and may result in severe mutilation. The porphobilinogen testf is negative.
2. Acute intermittent: Excretion of large amounts of the zinc complex of
uroporphyrin and coproporphyrin during episodes associated with gastrointesti-
nal, psychiatric, or neurological symptoms. Light sensitivity is usually lacking.
The porphobilinogen test is positive during attacks.
3. Chronic (mixed, hepatic, tardive, congenital): Uroporphyrin and copro-
porphyrin excretion is considered to be the zinc complex. Cutaneous changes
including bullae resulting from exposure to sunlight and local trauma, hyper-
pigmentation and hypertrichosis, may be present. Indulgence in alcoholic bever-
ages and functional impairment of liver are frequent findings. The porphobilino-
gen may be positive or negative.
Therapy of congenital, acute and chronic porphyria has always been unsat-
isfactory.
However, in 1938 Dobriner and co-workers (2) demonstrated that large
amounts of crude liver extract administered intramuscularly appreciably reduced
the urinary and fecal coproporphyrin excretion in two cases of congenital por-
phyria. This was associated with clinical improvement. The amount of liver
extract required to produce these effects was very large and for this reason it was
necessary to discontinue it and this was followed by relapse. Subsequent adminis-
tration of smaller amounts of liver extract by injection or large amounts by mouth
were found to be ineffective.
* From the Section of Dermatology (Dr. Stephen Rothman, Chief of Service), Depart-
ment of Medicine, University of Chicago.
This work was supported in part by two grants from the Squibb Institute for Medical
Research and in part by an Institutional Research Grant from the American Cancer Society.
The Vitamin B12 used in this study was kindly supplied by E. R. Squibb & Sons, Inc.,
New York, New York.
Read before the Thirteenth Annual Meeting of The Society for Investigative Derma-
tology, Inc., Chicago, Illinois, June 7, 1952.
f Porphobilinogen is a chromogen appearing in the urine in some cases of porphyria.
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The isolation of Vitamin B12 as one of the more important factors in liver
extract influencing the hematopoictic system, prompted us to evaluate its effect
on porphyria since it would be possible to administer amounts of pure B12 much
in excess of the B12 concentration in the largest amount of liver extract that could
feasibly be given.
In order to evaluate the effect of Vitamin B12 it would be necessary to deter-
mine the urinary porphyrin excretion regularly. If this was to be done then a
better method had to be developed, since available methods were laborious, time
consuming, and only roughly quantitative even in the best hands.
In 1951 Schwartz (3) introduced an extremely accurate method for quantita-
tive estimation of total urinary coproporphyrin that could be executed in half an
hour which involved the measurement of the porphyrin fluorescence in five cubic
centimeters of urine by a highly sensitive and specific fluorimeter. Following
Schwartz's suggestion we modified this method for the estimation of both uro-
porphyrin and coproporphyrin in urine and feces.
The method nsed is as follows: To each 24 hour specimen approximately 15 gm. of sodium
carbonate is added as a preservative. This was added to the collection bottle either before
collection of specimen was started or immediately thereafter. Specimens awaiting analysis
were stored in the icebox. An aliquot of from 2.5 to 10 cc. of urine is selected depending on
the porphyrin concentration in the urine as determined by previous analysis or by the
"rough" test. This aliquot is thoroughly agitated with 20 cc. of acetic acid buffered solution
(3), and 100 cc. of ethyl ether in a separatory funnel. The aqueous layer is separated from the
ether fraction and saved. The ether fraction which now contains the coproporphyrin is
washed two times with 100 cc. portions of 1% aqueous sodium acetate solution. The purpose
of the washes is to remove any small amount of uroporphyrin that might have gone into the
ether. These washings are saved and later combined with the original aqueous portion. The
ether is then washed with 100 cc. of .005 per cent aqueous iodine solution (freshly prepared).
The iodine wash is discarded. The ether layer is then washed repeatedly with small portions
of 1.5 normal hydrochloric acid until no red fluorescing material is further extractable from
the ether. The hydrochloric acid fractions are combined and the fluorescence measured as
eoproporphyrin against a standard solution of coproporphyrin* in a photo-fluorimeter of
the type described by Schwartz (3).
The combined aqueous portions (the original aqueous portion and the 1% sodium acetate
washes) are extracted twice with 100 cc. portions of normal butyl alcohol. After separation
of all the watery portion possible the butyl alcohol, now containing the uroporphyrin, is
extracted repeatedly with small portiocs of 1.5 normal hydrochloric acid until no red
fluorosing material is further extractable into hydrochloric acid. At the time of adding the
initial portion of hydrochloric acid, 20 cc. of petroleum ether is also added to the hutyl
alcohol. The fluorescence of the combined hydrochloric acid portions is then measured
against a standard uroporphyrin I solution in the photo-fluorimeter.
For focal porphyrin determinations, the total specimen is weighed and a five gram portion
is separated and mixed well with 50 cc. of 7.5 normal hydrochloric acid. This is allowed to
stand 24 hours and then is diluted with 150 cc. of distilled water; 2.5 cc. of this diluted mate-
rial is then treated the same way as urine for determination of uroporphyrin and copropor-
phyrin.
Data on a group of analyses using this technique involving the addition of
known amounts of chemically pure porphyrin to urine to establish the validity of this
method, are shown in Table 1.
* We are indebted to Dr. Samuel Schwartz for the coproporphyrin standard solution used
in this work.
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In addition we also developed a "rough" test which may be applied to urine, that makes
it possible to estimate total urinary porphyrin (both uro- and eoproporphyrin) in a few
minutes. This involves the dilution of a small quantity of urine with 1.5 normal hydrochloric
acid to at least twenty times its initial volume and measuring its fluorescence as uropor-
phyrin against a standard uroporphyrin solution. The dilution of twenty times or more
(frequently we dilute two hundred times) is necessary to establish a clear colorless solution
which is essential to establish a satisfactory measurement of fluorescence by this fluorim-
eter, to eliminate the possible quenching effect of other constituents of urine on the
fluorescence and to establish a constant pH.
TABLE I
Recoeery of copro and uroporphyrin from urine by the ether-but p1 alcohol analytical procedure
ADDED COPRO' RECOVERED COPRO ADDED UR0* RECOVERED URO TORY
3
9
15
21
3
9
15
21
100
100
100
100
44
79
56
29
43
75
53
29
98
95
94
100
* Copro and I.Jro values are expressed in arbitrary units.
TABLE II
Results by "rough test" compared with regular analysis
PATIENT TOTAL COPRO AND UROPORPHYRINBY ANALYSIS
TOTAL PORPHYRIN OBTAINED BY
"ROUGH" TEST
Patient A
Patient B
Patient C
2.44 mg.
3 32
1 96
1 40
1 07
2 00
16 7
95
12 9
14 8
19,0
22.4
25.4
32.8
2.74 mg.
3.22
197
1.44
1.06
2.88
15.9
9.3
13.5
14.8
20 2
22.9
26 2
33.6
Comparison of the results of this procedure with regular aualytical procedure is
shown in Table II.
The porphyrin excretion of two women and one man with chronic porphyria
was studied in conjunction with experimental therapy with Vitamin B52.
All had complained of hullae on the dorsum of the hands following mild trauma
particularly in the summer and early autumn. Occasionally bu!lae had occurred
on the face or ears without the association with trauma. Two patients had hyper-
pigmentation of the exposed part and hypertrichosis of the face. All three pa-
tients gave a history of chronic moderate alcoholic intake and one patient had
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taken a sedative nightly for years which in the past several years had been
chioral hydrate.
On initial examination the urine of all three patients was red or port wine
colored. A red fluorescence was easily demonstrable in each case when viewed
under the Wood light.
The porphobilinogen test (4) was carried out repeatedly during the past one
and a half years on all three patients and was consistently negative. Examination
of the native urine spectroscopically has always revealed the urine to have the
characteristic absorption bands of the zinc complex.
Case 1. The first study was on a 49 year old female physical education instruc-
tor with hypertrichosis of the face and hyperpigmentation of the exposed skin.
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FIG. 1. Case 1. The points joined by lines represent daily determinations; the blocks
represent the average of seven daily determinations.
She had noted the appearance of bullae on her fingers following mild trauma.
Every evening for over twenty years the patient consumed one or two cocktails.
The patient was hospitalized in the metabolic study ward on a diet containing
a fixed content of meat and a constant fluid intake. The alcoholic intake was
stopped at this time also. The results of this study are shown in Figure 1. During
a control period, the uroporphyrin ranged between 9.3 mg. and 5.8 mg. with an
average of 7.23. The daily urinary coproporphyrin ranged between 710 gamma
and 400 gamma with an average of 480 gamma. Normal urine contains 50 to 250
gamma per 24 hours of coproporphyrin and no detectable uroporphyrin.
Subsequently with the administration of Vitamin B12, 120 gamma per day for
17 days, the urinary coproporphyrin and uroporphyrin gradually declined over
a period of 16 days to a level significantly lower than during the control period.
After this period of therapy the Vitamin B12 was discontinued. Porphyrin excre-
tion continued to fall for several days and then rose again but not to the previous
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levels. Again Vitamin B12 was administered and again the urinary porphyrin
excretion declined. Fecal uroporphyrin and coproporphyrin determinations were
carried out as shown in Figure 2. It was considered possible that the decrease in
urinary porphyrin excretion was a reflection of the liver's enhanced ability to
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Fin. 2. Case 1. The blocks represent the average of groups of daily determinations.
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FIG. 3. Case 1. Each column represents an individual determination
excrete porphyrin in the feces. The fecal porphyrin did not however increase but
rather the coproporphyrin decreased and the uroporphyrin remained constant.
Continued administration of Vitamin B12, 75 gamma daily, and I olic acid, 5
mg. daily, orally, and estimation of urinary porphyrin excretion during the next
year shows that the porphyrin excretion has gradually fallen until the copropor-
phyrin level is within normal limits, and that the uroporphyrin level is less
than 50 gamma per day (Figure 3).
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FIG. 4. Case 1. Left, showing hypertrichosis of the right cheek (Oct. 1950). Right, loss of
hypertrichosis accompanying decrease in porphyrin excretion (Jan. 1952).
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The October, 1951 determination shown in Figure 3 indicates a significant ele-
vation of the coproporphyrin and uroporphyrin. Upon questioning the patient,
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FIG. 5. Case 2. Vitamin B12 was administered for nine weeks at the rate of 1000 gamma
daily, five days per week.
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she stated that she had again resumed the Cocktails, hut as indicated by the sub-
sequent fall in porphyrin excretion, this has been stopped.
Clinically this patient has shown much improvement in her general well being.
The hypertrichosis has subsided without local treatment (Figure 4) and there
have been no builae since therapy was started.
Case 2. The second patient was a 42 year old machinist whose only symptom
was bnllae on the dorsum of the hands that had recurred during the summer and
early autumn for the past four years. Re was allowed to continne his alcoholic
intake and after a control period he received 1000 gamma of Vitamin B12 daily
intramuscularly five days a week for nine weeks. The results of porphyrin deter-
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Fin. 6. Case 3. Each column represents an individual determination
minations carried out at intervals are shown in Figure 5. There was no significant
lowering of urinary porphyrin excretion nor was there any clinical improvement
that could be attributed to this therapy during the period of observation.
Case 3. The third patient was a 57 year old housewife with a long standing his-
tory of hyperpigmentation of the exposed parts and hypertrichosis of the face
and the occasional occurrence of a vesicle on the dorsum of the hands or face
during the summer months. Pruritus of the face has also been a prominent symp-
tom. This patient was allowed to continue her alcoholic intake and her nightly
dose of chloral hydrate. The periodic urinary porphyrin determinations and the
various types of Vitamin B12 therapy carried out between September, 1950 arid
April, 1952 are shown in Figure 6. There was no improvement in the porphyrin
excretion but rather it gradnally increased. There was no clinical improvement
in the patient.
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COMMENT
From studies on the first patient it would appear that the cessation of alcoholic
intake exerts a beneficial effect on abnormal porphyrin excretion. There is some
suggestion in this patient that Vitamin B12 is also helpful in improving the por-
phyrin excretion. During complete alcohol abstinence the porphyrin excretion
of this patient dropped during Vitamin B12 medication and rose when medication
was discontinued. However, this effect was not sufficiently pronounced to warrant
a definite conclusion. T\vo other patients receiving Vitamin B12 and in whom alco-
holic intake was unaltered showed no improvement in porphyrin excretion.
Since the completion of this work, Gray and Neuberger (5) in a recent article
state that Vitamin B12 had no beneficial effect on a case of congenital porphyria.
SUMMARY
1. An improved method for the analytical estimation of coproporphyrin and
uroporphyrin is presented. A simple technic for the estimation of total urinary
porphyrin is described.
2. Studies of porphyrin excretion of three patients with chronic porphyria in
conjunction with Vitamin B12 therapy are presented.
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DISCUSSION
DR. THEODOEE C0RNBLEET, Chicago, Ill.: It has been shown that anything
that disturbs the liver will increase porphyrin excretion and that anything that
will improve liver disease lessens it. Porphyrins increase in lupus erythematosus,
dermatomyositis and even with extensive cases of psoriasis. The porphyrin prob-
lem is baffling and complex. The same disease, apparently, such as epidermolysis
bullosa, may be present with no abnormal porphyrins and at other times when
they are plentiful. At the Cook County Hospital we now have a typical case of
porphyria with hypertrichosis and melanosis. I hope there will be an opportunity
to try the B-12 form of treatment in her case. When the porphyria improves, do
the hyperpigmentation and hirsutism recede?
DR. CALVIN J. DILLAHA, Litlic Rock, Ark.: The difference between the mean-
ing of the terms porphyria and porphyrinuria, II think, is well worth pointing out
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since these terms are frequently confused and used synonymously. The term por-
phyria refers to a definite disease entity. Although it may manifest itself in several
different clinical pictures, the excretion of uroporphyrin is uniformly present and
only by its isolation and identification is the diagnosis of this disease established
beyond doubt.
On the other hand, porphyrinuria is used to refer to the symptomatic elevation
of the normal constituent of urine, corproporphyrin, which may accompany sys-
temic disease or metabolic changes. Porphyrinuria is not associated with the
excretion of uroporphyrin.
There can be little doubt as to the importance of study of the porphyrins and
porphyrin metabolism in mammals, since it is an important constituent of sev-
eral respiratory enzymes such as hemoglobin and myoglobin.
